August 2012
-
DPI device developer Iconovo AB announced that it has raised €.2.3 million in an oversubscribed share issue, which the company will use to fund expansion of its services to include drug formulation development. As part… Read more . . .
-
According to Spyryx Biosciences, Cystic Fibrosis Foundation Therapeutics (CFFT) will increase a development award to Spyryx to provide a total of up to $5 million. The company said that it plans to use the funds… Read more . . .
-
Boehringer Ingelheim has filed a citizen petition with the FDA asking the agency to “request the Commissioner of Food and Drugs to ensure that any New Drug Application (“NDA”) for a fixed-dose, triple-combination, inhaled drug… Read more . . .
-
Consort Medical, parent company of device manufacturer Bespak and CDMO Aesica, has announced that its pre-tax profits for fiscal year 2017 almost doubled from FY 2016, rising from £11.3 million to £21.9 million. Bespak earnings… Read more . . .
-
Medical Developments International (MVP) has announced that Health Canada has accepted its submission for the Penthrox methoxyflurane inhaler, triggering a $250,000 Canadian milestone payment to MVP from Purdue Pharma Canada. In September 2016, MVP announced… Read more . . .
-
According to Novartis, the FDA has accepted Sandoz’s abbreviated new drug application for its generic version of the Advair Discus (Seretide Accuhaler) fluticasone propionate/salmeterol DPI for the treatment of asthma and COPD. The company acquired… Read more . . .
-
The 21st Congress of the International Society for Aerosols in Medicine (ISAM), held in Santa Fe, New Mexico June 3-7, 2017 featured presentations and posters covering recent advances in a wide range of topics related… Read more . . .
-
Sun Pharma Advanced Research Company Ltd. (SPARC) has announced that its SPARC DPI salmeterol 25 µg/fluticasone propionate 50 µg dry powder inhaler failed to show bioequivalence to Seretide Accuhaler (Advair Diskus) salmeterol 50 µg/fluticasone propionate… Read more . . .
-
Inhaled drug developer Pulmatrix announced that it has licensed a portfolio of kinase inhibitors from Janssen Biotech subsidiary RespiVert that it plans to develop as inhaled therapies for respiratory diseases. According to a form filed… Read more . . .
-
Pharmaxis has announced that its pivotal Phase 3 trial of Bronchitol mannitol DPI in adult patients with cystic fibrosis met its primary endpoint of change in FEV1 from baseline over the 26-week treatment period; however… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland